Product Description
Mechanisms of Action: HER3 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Squamous Cell Carcinoma|Head and Neck Cancer|Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01911598 |
R/M SCCHN | P1 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2017-06-22 |
2019-03-19 |
Treatments |
|
NCT01986166 |
GO29030 | P1 |
Completed |
Sarcoma |
2016-01-01 |
2019-03-20 |
Treatments |